SAN DIEGO and WOODCLIFF LAKE, N.J., Oct. 6, 2010 /PRNewswire via COMTEX News Network/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) and Eisai Inc. announced today upcoming lorcaserin presentations at Obesity 2010, the 28th Annual Scientific Meeting of The Obesity Society, in San Diego, California.
SAN DIEGO, and WOODCLIFF LAKE, N.J., Sept 16, 2010 /PRNewswire via COMTEX News Network/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) and Eisai Inc. announced today that the US Food and Drug Administration (FDA) Endocrinologic and Metabolic Drugs Advisory Committee voted 9 to 5 that the available
Arena Pharmaceutcals raises IPO to 6 mln shares WASHINGTON, July 25 (Reuters) - Arena Pharmaceuticals Inc. on Tuesday raised its initial public offering (IPO) to 6 million shares of common stock from 5 million shares. The company, which says it has developed technology that identifies drug
Arena Pharmaceuticals and Axiom Biotechnologies Sign Binding Letter of Intent for Research Collaboration and Equity Investment by Arena in Axiom SAN DIEGO--(BW HealthWire)--April 25, 2001-- The Collaborative Research Program Will Begin Immediately, and Arena's Purchase of $2 Million of Axiom
SAN DIEGO , July 25, 2013 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) today announced that its wholly owned subsidiary, Arena Pharmaceuticals GmbH , has entered into an exclusive marketing and supply agreement with CY Biotech Company Ltd.